3例主动脉瓣机械瓣置换术后获得性华法林 抵抗：基因检测及用药调整策略
3 Cases of Acquired Warfarin Resistance after Mechanical Aortic Valve Replacement: Genetic Testing and Medication Adjustment Strategies
摘要: 本文报告3例主动脉瓣重度反流患者的临床特征、治疗和围手术期抗凝管理。强调华法林基因检测和用药剂量指导在主动脉瓣机械瓣置换术后获得性华法林抵抗中的重要作用。
Abstract: This article reports the clinical characteristics, treatment, and perioperative anticoagulation management of three patients with severe aortic regurgitation. It emphasizes the significant role of genetic testing for warfarin and dosage guidance in cases of acquired warfarin resistance following mechanical aortic valve replacement.
文章引用：谢驰洋. 3例主动脉瓣机械瓣置换术后获得性华法林 抵抗：基因检测及用药调整策略[J]. 临床医学进展, 2026, 16(3): 1091-1097. https://doi.org/10.12677/acm.2026.163884

参考文献

[1] Link, K.P. (1959) The Discovery of Dicumarol and Its Sequels. Circulation, 19, 97-107. [Google Scholar] [CrossRef] [PubMed]
[2] Eikelboom, J.W., Connolly, S.J., Brueckmann, M., Granger, C.B., Kappetein, A.P., Mack, M.J., et al. (2013) Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. New England Journal of Medicine, 369, 1206-1214. [Google Scholar] [CrossRef] [PubMed]
[3] Otto, C.M., Nishimura, R.A., Bonow, R.O., Carabello, B.A., Erwin, J.P., Gentile, F., et al. (2021) 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 143, e72-e227. [Google Scholar] [CrossRef] [PubMed]
[4] Praz, F., Borger, M.A., Lanz, J., Marin-Cuartas, M., Abreu, A., Adamo, M., et al. (2025) 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. European Heart Journal, 46, 4635-4736. [Google Scholar] [CrossRef] 
[5] Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H., et al. (2004) Mutations in VKORC1 Cause Warfarin Resistance and Multiple Coagulation Factor Deficiency Type 2. Nature, 427, 537-541. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, M., Zeraatkar, D., Obeda, M., Lee, M., Garcia, C., Nguyen, L., et al. (2021) Drug-Drug Interactions with Warfarin: A Systematic Review and Meta‐Analysis. British Journal of Clinical Pharmacology, 87, 4051-4100. [Google Scholar] [CrossRef] [PubMed]
[7] Johnson, J.A. (2012) Warfarin Pharmacogenetics: A Rising Tide for Its Clinical Value. Circulation, 125, 1964-1966. [Google Scholar] [CrossRef] [PubMed]
[8] Sconce, E., Avery, P., Wynne, H. and Kamali, F. (2006) Vitamin K Supplementation Can Improve Stability of Anticoagulation for Patients with Unexplained Variability in Response to Warfarin. Blood, 109, 2419-2423. [Google Scholar] [CrossRef] [PubMed]
[9] Rieder, M.J., Reiner, A.P., Gage, B.F., Nickerson, D.A., Eby, C.S., McLeod, H.L., et al. (2005) Effect of vkorc1 Haplotypes on Transcriptional Regulation and Warfarin Dose. New England Journal of Medicine, 352, 2285-2293. [Google Scholar] [CrossRef] [PubMed]
[10] Aithal, G.P., Day, C.P., Kesteven, P.J. and Daly, A.K. (1999) Association of Polymorphisms in the Cytochrome P450 CYP2C9 with Warfarin Dose Requirement and Risk of Bleeding Complications. The Lancet, 353, 717-719. [Google Scholar] [CrossRef] [PubMed]
[11] Caldwell, M.D., Awad, T., Johnson, J.A., Gage, B.F., Falkowski, M., Gardina, P., et al. (2008) CYP4F2 Genetic Variant Alters Required Warfarin Dose. Blood, 111, 4106-4112. [Google Scholar] [CrossRef] [PubMed]
[12] International Warfarin Pharmacogenetics Consortium, Klein, T.E., Altman, R.B., Eriksson, N., Gage, B.F., Kimmel, S.E., et al. (2009) Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. The New England Journal of Medicine, 360, 753-64.
[13] Scott, O., Galicia-Connolly, E., Adams, D., Surette, S., Vohra, S. and Yager, J.Y. (2012) The Safety of Cruciferous Plants in Humans: A Systematic Review. Journal of Biomedicine and Biotechnology, 2012, Article ID: 503241. [Google Scholar] [CrossRef] [PubMed]

为你推荐